



Neville Bassett AM appointed to PharmAust Board

2 October 2018 – Perth, Australia: PharmAust Limited (ASX:PAA) is pleased to announce that Mr Neville Bassett AM has been appointed as a non-executive director to the PharmAust Board.

Mr Bassett is a Chartered Accountant specialising in corporate, financial and management advisory services. He has been involved with numerous public company listings and capital raisings.

Mr Bassett is chairman of Westar Capital Limited and is a director or company secretary of a number of public and private companies.,

His corporate experience in Australian financial markets includes mergers and acquisitions. He has extensive experience in the Corporations Act, ASX listing requirements, corporate taxation and finance.

He is a Fellow of Chartered Accountants Australia and New Zealand and holds an Australian Financial Services Licence. He was a Director/Councillor of a major not-for-profit organisation for 26 years, serving eight years as Chairman before his retirement in 2017. Mr Bassett was awarded a Member of the Order of Australia (AM) in the 2015 Australia Day Honours.

Concurrently, Dr Wayne Best will retire as a non-executive director of PharmAust. Dr Best has made an invaluable contribution to PAA and its wholly owned subsidiary Epi chem Pty Ltd. The PharmAust Board acknowledges Dr Best's contribution and wishes him well in his future endeavours. Dr Best will remain on the Epi chem board and continue to act as Chairman of Epi chem.

PharmAust's Executive Chair and CEO Dr Roger Aston said, "We are delighted to welcome Neville to our board at a particularly promising stage in the Company's growth and pleased that Wayne will remain as chair of Epi chem, which he founded in 2003."

The material terms of the engagement is set out in the Schedule.

Enquiries:

**Enquiries:
Dr Roger Aston
Executive Chairman & CEO
Tel: 0402 762204**

**Mr Robert Bishop
Executive Director
Tel: 0417 445 180**

Schedule

Material terms of engagement of Neville Bassett	
Appointment	As Non-Executive Director of PharmAust Limited
Commencement	The appointment commences with effect on 1 October 2018.
Payment	Directors fee of \$30,000 p.a. (plus statutory superannuation).

About Epichem:

Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Technology Park, Western Australia, Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in 35 countries worldwide for over 12 years. Epichem has a newly constructed state-of-the-art laboratory and has world class equipment and expertise in synthetic and medicinal chemistry for the cost-effective synthesis of drug analogue libraries and intermediates. It also has a rapidly growing catalogue of pharmaceutical reference standards. More information at www.epichem.com.au

About PharmAust (PAA):

PAA is a clinical-stage company developing targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated ~Aus\$3.05m in revenues in the 2017 FY

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway - a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs. MPL treatment was well-tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug into Phase 2 clinical trial.